The Experts in Animal Health

Brakke Consulting’s
Animal Health News & Notes for April 8, 2022
Copyright © Brakke Consulting
Editor: Lynn Fondon DVM MBA
For All News & Notes Subscribers: At the end of April, we will move to a new platform to host and deliver this newsletter.  To keep our subscriber database up to date, we would like you to update your profile, which can be done here.   It will take just a minute of your time.  We will keep the same well-liked format and will continue sending it out on Friday mornings. Thanks for subscribing – we appreciate it.


Brakke Consulting News
Brakke Recruiting – open position for Head of Swine Segment
2022 Pain Management Products report – last week to pre-order

Earnings News
Boehringer Ingelheim
Cal-Maine Foods

Other News
Brakke Consulting
DS Pharma Animal Health
Equus Innovations
Jorgensen Laboratories
Main Street Capital
Norbrook Labs
Oasmia Pharmaceutical
Osso VR
Sumitomo Pharma Animal Health
Vertical Vet

Brakke Consulting
Opportunity in China for Head of Swine Segment 

BI China seeks a Head of Swine Segment in its Shanghai office. The position is responsible for overall management of the high-profile swine business there. Reporting to the Head are marketing, sales, technical services, and administration. The primary goal is to build and lead an efficient team, achieving short- and long-term goals and commit aggressively to strategic development in China, working with Country and Corporate leadership. 10-15 years’ experience required, MBA preferred. Proficiency in English required, as is demonstrated success working in a foreign country and culture.

Click here for details or to apply.

  • Boehringer Ingelheim reported results for the year 2021. Animal Health net sales were 4.3 billion EUR ($4.7 billion), an increase of 5% year-over-year (+6% currency adjusted). US sales were EUR 1.82 billion ($2.0 billion), essentially flat compared to the prior year. (company press release, IHS Markit Connect)
  • Cal-Maine Foods reported results for its fiscal third quarter ended February 26, 2022. Net sales were $477.5 million, an increase of 33% compared to the third quarter of fiscal 2021. Net income was $39.5 million, compared to net income of $13.5 million in the prior-year quarter. (Feedstuffs)

Brakke Consulting

Pain management is one of the leading topics in veterinary medicine today. Brakke Consulting’s annual report on Pain Management Products for Dogs and Cats includes such valuable information as:

– estimates of US sales and prices of leading products
– new and upcoming pain management products, including ZORBIUM and monoclonal antibody products LIBRELA and SOLENSIA
– discussion of the use of cannabinoids in veterinary pain management
– 2022 survey of 359 small animal veterinarians regarding use of pain management products

NEW THIS YEAR! The report will feature trended, aggregated dispensing data provided by VetSuccess, including chronic vs. acute use of analgesics, comparisons of analgesic revenue per patient by brand, and data on brand-switching at the patient level.

Pain Management Products for Dogs and Cats 2022 can be purchased for $8,750 if ordered by April 15, 2022, and $9,495 thereafter. The report will be completed in late April. Questions about the study can be answered by project manager Lynn Fondon, DVM, MBA at   .

  • Zoetis and Merck announced that they have been chosen by the OIE as the two new suppliers for the organization’s global rabies vaccine bank. The companies will supply the bank for an initial duration of four years from 2022 to 2025. (IHS Markit Connect)
  • Jorgenson Laboratories announced a minority investment from Main Street Capital Corporation. The Jorgenson family will retain operational control and majority ownership of the company, which sells equipment to the veterinary profession under the Jorvet brand. Brakke Consulting advised Jorgensen Laboratories on the transaction. (company press release)
  • The FDA announced it has approved Virbac‘s Tenotryl (generic enrofloxacin injectable) for control of bovine respiratory disease in beef and non-lactating dairy cattle and swine. (FDA)
  • The FDA announced it has approved Norbrook Labs‘ Midamox (generic imidacloprid + moxidectin) topical solution for cats; Enroflox (generic enrofloxacin) chewable tablets for use in dogs and cats; and Tulieve (generic tulathromycin injection) for use in beef and non-lactating dairy cattle, calves, and swine. (FDA)
  • Dechra and Vetcare announced an agreement wherein Dechra is Vetcare’s exclusive licensing partner for the recently approved Zenalpha. Dechra will become the marketing authorization (MA) holder in the US, while Vetcare will remain the MA holder in the EU where the drug was approved in December 2021. (company press release)
  • Purina announced the launch of Pro Plan Calming Care Veterinary Supplements for Cats. The Calming Care supplements, once available only to dogs, are formulated with the BL999 strain of bacteria, which has proven to aid in calm behavior, and vitamin E, which acts as a cortisol blocker to decrease stress and increase immune health. (
  • Zomedica announced the commercial launch of its newest assay – endogenous ACTH (eACTH) – for the TRUFORMA In-Clinic Biosensor Testing Platform, offering veterinarians the ability to quickly differentiate between pituitary dependent (PDH) and adrenal dependent (ADH) Cushing’s syndrome to inform management for the disease. (
  • Equus Innovations and AlphaLogix have partnered to launch the AlphaFlo canine allograft in the US market. AlphaFlo is an acellular, liquid canine amniotic tissue allograft that is designed to supplement and protect tissues. (IHS Markit Connect)
  • Oasmia Pharmaceutical announced it has changed its name change to Vivesto, following a rights issue in January in which around 48.37 million shares – corresponding to 53.9% of total shares offered – were subscribed. The rights issue generated around SEK151 million ($16.2 million) before issue costs for Vivesto. (IHS Markit Connect)
  • Fidelis Pharmaceuticals announced that the company will now be known as Fidelis Animal Health. The company’s initial product offering, Ethiqa XR, is an innovative formulation of buprenorphine indicated for the control of post-procedural pain in mice and rats. (PRNewswire)
  • PetSmart announced an exclusive partnership with Nom Nom, a direct-to-consumer (DTC) fresh frozen dog food brand, to make Nom Nom available in select PetSmart stores and nationwide through The collaboration takes Nom into brick-and-mortar stores for the first time. (PRnewswire)
  • Orthomed announced it is partnering with Osso VR to bring the Osso’s virtual reality (VR) surgical training platform to the animal health market. The technology will give veterinarians access to VR training and allow them to practice procedures in VR to increase positive outcomes for surgery in real life. The first module will focus cruciate ligament repair surgery for dogs. (
  • Vimian announced it has acquired Vertical Vet, a provider of procurement and support services to veterinary clinics in the US with around $6 million in revenues in 2021. Its services are used by more than 1,100 member clinics. Financial terms were not disclosed. (IHS Markit Connect)
  • EU Vetoquinol announced the launch of Felpreva (tigolaner, emodepside and praziquantel) every-three-month topical feline antiparasitic in five European markets. The spot-on solution is now available in France, Germany, the UK, Austria and Italy. (IHS Markit Connect)
  • JAPAN DS Pharma Animal Health has changed its name to Sumitomo Pharma Animal Health. (IHS Markit Connect)
  • SPAIN Nuzoa announced it has signed an agreement to acquire Dogerty, the main distributor in the South and South-West of Spain with focus on livestock and companion animal businesses. Turnover of both companies are around EUR 135 million ($148 million). Financial terms were not disclosed. (company press release)



  • US – AVIAN INFLUENZA RESEARCH Researchers at the Pirbright Institute have discovered a novel avian influenza vaccine potentially protects birds from the H9N2 strain of avian influenza as soon as they hatch by avoiding interference from those maternal antibodies that protect the chick in the first few weeks of life. The research was published in npj Vaccines. (Feedstuffs)
  • TAIWAN – PET CARE Taiwan announced it will launch a new government department for pets this month. The new section in the country’s Council of Agriculture will oversee all aspects of pets’ lives, from pet food to grooming, training, pet-sitting, and pet insurance. Nearly 1 in 3 households in Taiwan are registered as having pets. (GlobalPets)

The Michigan House is considering a bill to codify the ability for veterinarians to conduct telehealth exams without prior in-person visits. Currently, these are allowed there only in emergencies or when the patient is a shelter pet. While some cite the convenience offered, others, including the MVMA, oppose the proposal. Their argument relates to upholding a doctor-patient relationship. Though a vigilant pet parent may be finely attuned, the pets do not talk.

Some may recall that the State of Colorado once considered legislation equating pets to members of the household, such as children. That, too, was opposed locally due to concerns over potentially skyrocketing legal cases and fees.

Brakke Consulting conducted an in-depth review of telemedicine in the veterinary industry and could not find that the practice has gained any traction. Undoubtedly, the service is widely available and touted, but apparently not popular with veterinarians. In fact, uptake was found to be nearly negligible.

Still,  research with pet owners has found that they find the concept quite appealing: a 2020 survey found that nearly half would like their veterinary practice to offer digital/remote consultations

What do you think? Is this an idea whose time has come? Does convenience trump veterinary familiarity?
Jeff Santosuosso

Last week’s poll asked about the amount of information about companies and veterinary practice activities. About 1/3 answered that the amount is just right. About 1 in 5 asked for more information about each of those two topics, while about 1 in 4 asked for more information about both of those topics. We strive to make the newsletter as useful as possible for all. Thanks for the feedback.

This week
Have you ever had a telemedicine appointment, for yourself or a family member, or pet?

en_USEnglish (United States)